US-based biotechnology company Protext Mobility has reached an agreement with Plandai Biotechnology to acquire Cannabis Biosciences by acquiring 100% of the capital stock of the target company in exchange for 50 million shares of the acquirer company’s common stock.

All companies involved in the transaction are based in the US.

The target company develops non-psychoactive medicines from a live cannabis plant.

Protext Mobility expects the acquisition to enable it to extend its studies on cannabis.

"The acquirer company’s stake in the target JV company will increase to 60% following the acquisition, while TaiGen Biopharmaceuticals will hold the remaining 40%."

TaiGen Biopharmaceuticals (Beijing) has agreed to sell 9% equity stake in its joint venture (JV) subsidiary Dongguan HEC TaiGen Biopharmaceuticals to the joint venture partner Yichang Hec Changjiang Pharmaceutical.

The vendor company will receive $20m as purchase consideration for the transaction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquirer company’s stake in the target JV company will increase to 60% following the acquisition, while TaiGen Biopharmaceuticals will hold the remaining 40%.

All companies involved in the transaction are based in China.